Philadelphia based Interius BioTherapeutics recently dosed the first patient for its in vivo CAR therapy that edits T and NK cells in the body so they target CD20 positive cells in B-cell malignancies

V.P. of R&D Tim Culp describes the rationale for in vivo CAR programs, what the company will be watching for from a safety standpoint, the development path ahead, and competition.